Chloroquine Analogues as Leads against Pneumocystis Lung Pathogens

• Type: Article in International Scientific Journal
• Date: 2018

Authors

Gomes, A (Author) Other; Ferraz, R (Author) Other; Ficker, L (Author) Other; Collins, MS (Author) Other; Prudencio, C (Author) Other; Cushion, MT (Author) Other; Catia Teixeira (Author) FCUP; Paula Gomes (Author) FCUP

Journal

Title: Antimicrobial Agents and Chemotherapy

Vol. 62

ISSN: 0066-4804

Publisher: American Society for Microbiology

Indexing

ISI Web of Knowledge - 6 Citations

Scopus - 5 Citations

Other information

Authenticus ID: P-00P-T02

DOI: 10.1128/aac.00983-18

Abstract (EN): The impact of Pneumocystis pneumonia (PcP) on morbidity and mortality remains substantial for immunocompromised individuals, including those afflicted by HIV infection, organ transplantation, cancer, autoimmune diseases, or subject to chemotherapy or corticosteroid-based therapies. Previous work from our group has shown that repurposing antimalarial compounds for PcP holds promise for treatment of this opportunistic infection. Following our previous discovery of chloroquine analogues with dual-stage antimalarial action both in vitro and in vivo, we now report the potent action of these compounds on Pneumocystis carinii in vitro. Identification of chloroquine analogues as anti-PcP leads is an unprecedented finding.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 8